New Sugar-Tracking scan could reveal hidden inflammation
NCT ID NCT07253753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new radioactive tracer called NeuCaVis in 12 healthy volunteers. Unlike standard PET scans that track glucose, NeuCaVis follows fructose, which is only used by inflamed tissues. The goal is to check safety and how the tracer spreads in the body, potentially leading to clearer images of disease in the brain and heart.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
12 people
The number who actually took part.
- Started
-
Apr 2026
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, ages 18-55 years inclusively at time of consent 2. Body Mass Index (BMI) of 18 to 30 kg/m2, inclusively 3. Capable of providing informed consent 4. Able to speak and read in English or French 5. Able to comply with all study procedures (including fasting for 12 hours, lying still in a supine position for about 90 minutes) Exclusion Criteria: 1. Known hypersensitivity NeuCaVis or its excipients 2. Blood glucose level higher than 200mg/dl at screening 3. Active viral infection at screening 4. Currently taking anti-inflammatory medications (e.g. ASA, NSAIDs, corticosteroids, immunomodulating agents, colchicine) 5. Any anatomical heart abnormality, or cardiovascular condition including acute cardiac condition, suspicion of cardiac inflammation, and/or coronary artery disease, that may confound the analysis of the data based on the investigator's clinical opinion. 6. Recent (in the past 6 months) history of head trauma 7. Abnormal and clinically significant results on the physical examination, vital signs, or laboratory tests at screening. 8. Clinically significant neurologic, neurodevelopmental, cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, or metabolic-endocrine disorder 9. Female participants who are pregnant, planning to become pregnant during the study or breastfeeding 10. If of childbearing potential, unwilling or unable to use of a highly effective method of contraception as outlined in the protocol for the duration of the study. 11. Any contraindication to PET or CT imaging. 12. Actively participating in other interventional clinical trial(s). 13. Unwilling to comply with study procedures, medication restrictions or attend all study visits 14. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The effects of external nasal dilator strips on sleep and cardiovascular health
- A pharmacokinetic study of NTI164 in healthy adult volunteers
- Genetic determinants of Exercise-Induced muscle damage (POLYGENDOMUS) / déterminants génétiques des dommages musculaires induits par l'Exercice (POLYGENDOMUS)
- Can a simple injection timing reduce bleeding after skin cancer surgery?
- Can Land-Based teachings shape psychedelic therapy training?
- Can a new oral drug pass early safety tests?